These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Regulation of the kinin receptors after induction of myocardial infarction: a mini-review. Tschöpe C; Heringer-Walther S; Walther T Braz J Med Biol Res; 2000 Jun; 33(6):701-8. PubMed ID: 10829098 [TBL] [Abstract][Full Text] [Related]
29. Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation. Mage M; Pécher C; Neau E; Cellier E; Dos Reiss ML; Schanstra JP; Couture R; Bascands JL; Girolami JP Can J Physiol Pharmacol; 2002 Apr; 80(4):328-33. PubMed ID: 12025968 [TBL] [Abstract][Full Text] [Related]
30. The kallikrein-kinin system in diabetic nephropathy. Tomita H; Sanford RB; Smithies O; Kakoki M Kidney Int; 2012 Apr; 81(8):733-44. PubMed ID: 22318421 [TBL] [Abstract][Full Text] [Related]
31. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Farhy RD; Carretero OA; Ho KL; Scicli AG Circ Res; 1993 Jun; 72(6):1202-10. PubMed ID: 7684331 [TBL] [Abstract][Full Text] [Related]
32. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Mombouli JV Drugs; 1997; 54 Suppl 5():12-22. PubMed ID: 9429841 [TBL] [Abstract][Full Text] [Related]
33. Bradykinin receptor deficiency or antagonism do not impact the host response during gram-negative pneumonia-derived sepsis. Ding C; Yang J; Van't Veer C; van der Poll T Intensive Care Med Exp; 2019 Mar; 7(1):14. PubMed ID: 30874974 [TBL] [Abstract][Full Text] [Related]
34. [Endothelial mechanisms in vasomotor effects of ACE inhibitors]. Busse R; Hecker M Z Kardiol; 1994; 83 Suppl 4():1-6. PubMed ID: 7856274 [TBL] [Abstract][Full Text] [Related]
35. Kinins in cardiac inflammation and regeneration: insights from ischemic and diabetic cardiomyopathy. Savvatis K; Westermann D; Schultheiss HP; Tschöpe C Neuropeptides; 2010 Apr; 44(2):119-25. PubMed ID: 20036002 [TBL] [Abstract][Full Text] [Related]
36. Molecular interactions of vasoactive systems in cardiovascular damage. Bader M J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S7-9. PubMed ID: 11811382 [TBL] [Abstract][Full Text] [Related]
37. Cardiovascular properties of the kallikrein-kinin system. Sharma JN; Sharma J Curr Med Res Opin; 2002; 18(1):10-7. PubMed ID: 11999140 [TBL] [Abstract][Full Text] [Related]
38. Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade. Barker TA; Massett MP; Korshunov VA; Mohan AM; Kennedy AJ; Berk BC Hypertension; 2006 Nov; 48(5):942-9. PubMed ID: 16982965 [TBL] [Abstract][Full Text] [Related]
39. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation. Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485 [TBL] [Abstract][Full Text] [Related]
40. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. Zhang X; Recchia FA; Bernstein R; Xu X; Nasjletti A; Hintze TH J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]